Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.

De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H.

Carcinogenesis. 2014 Sep;35(9):2142-53. doi: 10.1093/carcin/bgu143. Epub 2014 Jul 1.

2.

A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.

Sackmann Sala L, Boutillon F, Menara G, De Goyon-Pélard A, Leprévost M, Codzamanian J, Lister N, Pencik J, Clark A, Cagnard N, Bole-Feysot C, Moriggl R, Risbridger GP, Taylor RA, Kenner L, Guidotti JE, Goffin V.

J Pathol. 2017 Sep;243(1):51-64. doi: 10.1002/path.4924. Epub 2017 Jul 28.

PMID:
28603917
3.

HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.

Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H.

Oncogene. 2016 Jul 21;35(29):3781-95. doi: 10.1038/onc.2015.444. Epub 2015 Dec 7.

4.

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.

Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.

PMID:
25220373
5.

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.

Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.

J Transl Med. 2015 May 8;13:150. doi: 10.1186/s12967-015-0509-x.

6.

Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ.

Carcinogenesis. 2012 Feb;33(2):404-12. doi: 10.1093/carcin/bgr290. Epub 2011 Dec 8.

7.

The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.

Tien JC, Liu Z, Liao L, Wang F, Xu Y, Wu YL, Zhou N, Ittmann M, Xu J.

Cancer Res. 2013 Jul 1;73(13):3997-4008. doi: 10.1158/0008-5472.CAN-12-3929. Epub 2013 May 6.

8.

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.

Toren P, Kim S, Johnson F, Zoubeidi A.

PLoS One. 2016 Apr 5;11(4):e0152861. doi: 10.1371/journal.pone.0152861. eCollection 2016.

9.

Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.

Qin J, Lee HJ, Wu SP, Lin SC, Lanz RB, Creighton CJ, DeMayo FJ, Tsai SY, Tsai MJ.

J Clin Invest. 2014 Nov;124(11):5013-26. doi: 10.1172/JCI76412. Epub 2014 Oct 8.

10.

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.

Oncotarget. 2016 Mar 29;7(13):15959-76. doi: 10.18632/oncotarget.7557.

11.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.

PMID:
23954373
12.

Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.

Le B, Powers GL, Tam YT, Schumacher N, Malinowski RL, Steinke L, Kwon G, Marker PC.

PLoS One. 2017 Mar 28;12(3):e0174658. doi: 10.1371/journal.pone.0174658. eCollection 2017.

13.

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.

Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C.

Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4.

14.

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.

Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM.

Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18.

15.

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.

Hu X, Garcia C, Fazli L, Gleave M, Vitek MP, Jansen M, Christensen D, Mulholland DJ.

Sci Rep. 2015 Nov 13;5:15182. doi: 10.1038/srep15182.

16.

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.

Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008.

17.

NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Yu C, Wu G, Li R, Gao L, Yang F, Zhao Y, Zhang J, Zhang R, Zhang J, Yao L, Yuan J, Li X.

Cancer Biol Ther. 2015;16(2):287-96. doi: 10.1080/15384047.2014.1002348.

18.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
19.

Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.

Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D.

Oncogene. 2014 Jul 10;33(28):3660-7. doi: 10.1038/onc.2013.342. Epub 2013 Sep 2.

20.

PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.

Jefferies MT, Cox AC, Shorning BY, Meniel V, Griffiths D, Kynaston HG, Smalley MJ, Clarke AR.

J Pathol. 2017 Dec;243(4):442-456. doi: 10.1002/path.4977. Epub 2017 Nov 14.

PMID:
29134654

Supplemental Content

Support Center